Nevertheless, despite low numbers in our cohort some mutations previously reported to be rare or absent in DLBCL were significantly more often observed in our primary samples (NOTCH1, MYC, RB1, FAT2, ATM, SMARCA4, MCL1) and relapsed samples (TP53, MCL1, ATM, FAT2, MYC, RB1, SMARCA4) (see Supplementary Tables S3 and S6) when compared to the literature of primary samples [7–12]. This evidence concerns the gene MCL1 and diffuse large B-cell lymphoma.